Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 880-888

  Patel, Sachin ^a   Rademacher, David J ^a   Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANANDAMIDE; AUTORECEPTOR; CANNABINOID; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; ENDOCANNABINOID; ETICLOPRIDE; METHYLPHENIDATE; QUINPIROLE; SKF 33939; UNCLASSIFIED DRUG; VANOXERINE;

ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; FOREBRAIN; LIMBIC CORTEX; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MENTAL DISEASE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SYNAPTIC TRANSMISSION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ARACHIDONIC ACIDS; DOPAMINE AGONISTS; ENDOCANNABINOIDS; GLYCERIDES; MALE; MICE; MICE, INBRED ICR; POLYUNSATURATED ALKAMIDES; PROSENCEPHALON; QUINPIROLE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0041932370     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054270     Document Type: Article

References (47)

1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, et al. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719.
2. Abraham WC and Huggett A (1997) Induction and reversal of long-term potentiation by repeated high-frequency stimulation in rat hippocampal slices. Hippocampus 7:137-145.
3. Auclair N, Otani S, Soubrie P, and Crepel F (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83:3287-3293.
4. Braver TS and Barch DM (2002) A theory of cognitive control, aging cognition and neuromodulation. Neurosci Biobehav Rev 26:809-817.
5. Calabresi P, Mercuri NB, Sancesario G, and Bernardi G (1993) Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:433-452.
6. Carboni E, Spielewoy C, Vacca C, Nosten-Bertrand M, Giros B, and Di Chiara G (2001) Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 141:141-144.
7. Cepeda C, Buchwald NA, and Levine MS (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580.
8. Cepeda C, Hurst RS, Altemus KL, Flores-Hernandez J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, et al. (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85:659-670.
9. Cepeda C and Levine MS (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1-18.
10. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376.
11. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, and Fernandez-Ruiz JJ (2000a) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627-1635.
12. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, and Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (Lond) 372:686-691.
13. Di Marzo V, Hill MP, Bisogno T, Crossman AR, and Brotchie JM (2000b) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438.
14. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
15. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, and Dewey SL (2000) Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Ther 295:51-57.
16. Gerdeman G and Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471.
17. Gerdeman GL, Ronesi J, and Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446-451.
18. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, and Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
19. Gough AL and Olley JE (1978) Catalepsy induced by intrastriatal injections of delta9-THC and 11-OH-delta9-THC in the rat. Neuropharmacology 17:137-144.
20. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, and Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900-6907.
21. Harrison MB, Wiley RG, and Wooten GF (1992) Changes in D2 but not D1 receptor binding in the striatum following a selective lesion of striatopallidal neurons. Brain Res 590:305-310.
22. Hillard CJ (2000) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 61:3-18.
23. Horvitz JC (2002) Dopamine gating of glutamatergic sensorimotor and incentive motivational input signals to the striatum. Behav Brain Res 137:65-74.
24. Horvitz JC, Williams G, and Joy R (2001) Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion. Psychopharmacology (Berl) 154:350-355.
25. Hsu KS, Huang CC, Yang CH, and Gean PW (1995) Presynaptic D2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res 690:264-268.
26. Huang CC, Lo SW, and Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (Lond) 532:731-748.
27. Keefe KA and Adams AC (1998) Differential effects of N-methyl-D-aspartate receptor blockade on eticlopride-induced immediate early gene expression in the medial and lateral striatum. J Pharmacol Exp Ther 287:1076-1083.
28. Kiyatkin EA and Rebec GV (1999) Striatal neuronal activity and responsiveness to dopamine and glutamate after selective blockade of D1 and D2 dopamine receptors in freely moving rats. J Neurosci 19:3594-3609.
29. Kuczenski R and Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037.
30. Leweke FM, Giuffrida A, Wurster U, Emrich HM, and Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669.
31. Lichtman AH, Varvel SA, and Martin BR (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66:269-285.
32. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, and Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018-1025.
33. Morgan JI and Curran T (1988) Calcium as a modulator of the immediate-early gene cascade in neurons. Cell Calcium 9:303-311.
34. Mortimer AM (1997) Cognitive function in schizophrenia-do neuroleptics make a difference? Pharmacol Biochem Behav 56:789-795.
35. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
36. O'Donnell P (2003) Dopamine gating of forebrain neural ensembles. Eur J Neurosci 17:429-435.
37. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (Lond) 385:634-636.
38. Pryor GT, Larsen FF, Husain S, and Braude MC (1978) Interactions of delta9-tetrahydrocarmabinol with D-amphetamine, cocaine and nicotine in rats. Pharmacol Biochem Behav 8:295-318.
39. Robbe D, Kopf M, Remaury A, Bockaert J, and Manzoni OJ (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99:8384-8388.
40. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, and Fernandez-Ruiz J (2002) The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological and therapeutic aspects. Pharmacol Ther 95:137-152.
41. Salamone JD, Correa M, Mingote S, and Weber SM (2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry and drug abuse. J Pharmacol Exp Ther 305:1-8.
42. Seamans JK, Durstewitz D, Christie BR, Stevens CF, and Sejnowski TJ (2001) Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 98:301-306.
43. Skirboll LR, Grace AA, and Bunney BS (1979) Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science (Wash DC) 206:80-82.
44. Stella N and Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425:189-196.
45. Stella N, Schweitzer P, and Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature (Lond) 388:773-778.
46. Wang J and O'Donnell P (2001) D(1) dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11:452-462.
47. Wang L, Liu J, Harvey-White J, Zimmer A, and Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 100:1393-1398.